Current Protein Identity:P21802 New Search
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
10OO FGFR2 mutant D650V with compound 4 (AZD3463) Deposited 2026-01-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Mutation:D650V A1C65 (4P)-N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 8.5;293 K;30% PEG 4,000, 200 mM Lithium Sulfate, 100 mM TRIS pH 8.5
Resolution 1.85 Å R-free 0.256
10OO FGFR2 mutant D650V with compound 4 (AZD3463) Deposited 2026-01-29 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Mutation:D650V A1C65 (4P)-N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 8.5;293 K;30% PEG 4,000, 200 mM Lithium Sulfate, 100 mM TRIS pH 8.5
Resolution 1.85 Å R-free 0.256
10OQ FGFR2 mutant D650V with compound 6 Deposited 2026-01-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Mutation:D650V A1C66 N-[(3M)-3-{5-chloro-2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}-1-methyl-1H-indol-6-yl]propanamide × 1 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 5.6;293 K;22% PEG 4,000, 200 mM Ammonium Sulfate, 100 mM Sodium Citrate pH 5.6
Resolution 1.98 Å R-free 0.251
10OQ FGFR2 mutant D650V with compound 6 Deposited 2026-01-29 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Mutation:D650V A1C66 N-[(3M)-3-{5-chloro-2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}-1-methyl-1H-indol-6-yl]propanamide × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 5.6;293 K;22% PEG 4,000, 200 mM Ammonium Sulfate, 100 mM Sodium Citrate pH 5.6
Resolution 1.98 Å R-free 0.251
10OU FGFR2 mutant D650V with compound 12 Deposited 2026-01-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Mutation:D650V A1C67 N-[(3M)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1-methyl-1H-indol-6-yl]propanamide × 1 EDO 1,2-ETHANEDIOL × 11 GOL GLYCEROL × 4 SO4 SULFATE ION × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 5.6;293 K;22% PEG 4,000, 200 mM Ammonium Sulfate, 100 mM Sodium Citrate pH 5.6
Resolution 1.77 Å R-free 0.213
10OU FGFR2 mutant D650V with compound 12 Deposited 2026-01-29 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Mutation:D650V A1C67 N-[(3M)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1-methyl-1H-indol-6-yl]propanamide × 1 EDO 1,2-ETHANEDIOL × 11 GOL GLYCEROL × 8 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 5.6;293 K;22% PEG 4,000, 200 mM Ammonium Sulfate, 100 mM Sodium Citrate pH 5.6
Resolution 1.77 Å R-free 0.213
1DJS LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1 Deposited 1999-12-03 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 32–36(5 aa) Fragment:IG-LIKE DOMAINS 2 AND 3
Chain A 152–362(211 aa) Fragment:IG-LIKE DOMAINS 2 AND 3
Mutation:N147T,S148L,N149E,N150P,K151E,R152G Non-standard monomer:Yes (specific site not provided by mmCIF) Mutation:N147T,S148L,N149E,N150P,K151E,R152G Non-standard monomer:Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 18 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;1.6M AMMONIUM SULFATE, 10MM TRIS (PH7.5), pH 7.50
Resolution 2.40 Å R-free 0.315
1DJS LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1 Deposited 1999-12-03 Assembly 2 Protein heterocomplex Heteromer;Protein × 8 PDB declaration: octameric(8) Consistent with protein count
Chain A 32–36(5 aa) Fragment:IG-LIKE DOMAINS 2 AND 3
Chain A 152–362(211 aa) Fragment:IG-LIKE DOMAINS 2 AND 3
Mutation:N147T,S148L,N149E,N150P,K151E,R152G Non-standard monomer:Yes (specific site not provided by mmCIF) Mutation:N147T,S148L,N149E,N150P,K151E,R152G Non-standard monomer:Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 36 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;1.6M AMMONIUM SULFATE, 10MM TRIS (PH7.5), pH 7.50
Resolution 2.40 Å R-free 0.315
1E0O CRYSTAL STRUCTURE OF A TERNARY FGF1-FGFR2-HEPARIN COMPLEX Deposited 2000-04-03 Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: pentameric(5) Consistent with all polymers
Chain B 148–366(219 aa)
Chain D 148–366(219 aa)
Not recorded NI NICKEL (II) ION × 5 SO4 SULFATE ION × 5 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.5;CRYSTALS WERE GROWN FROM: 1.0M LI2SO4, 0.1M TRISCL PH=8.5, 10MM NISO4, pH 8.50
Resolution 2.80 Å R-free 0.309
1EV2 CRYSTAL STRUCTURE OF FGF2 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 (FGFR2) Deposited 2000-04-19 Assembly 1 Protein heterocomplex Heteromer;Protein × 8 PDB declaration: octameric(8) Consistent with protein count
Chain E 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)
Chain F 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)
Chain G 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)
Chain H 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)
Not recorded SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, temperature 298.0K
Resolution 2.20 Å R-free 0.273
1GJO The FGFr2 tyrosine kinase domain Deposited 2001-07-31 Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 456–768(313 aa) Fragment:TYROSINE KINASE DOMAIN RESIDUES 465-768
Not recorded SO4 SULFATE ION × 8 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.9;32% AMMONIUM SULFATE, TRIS/MALEIC ACID BUFFER, PH 5.9
Resolution 2.40 Å R-free 0.256
1II4 CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 Deposited 2001-04-20 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain E 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366
Mutation:S252W No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.70 Å R-free 0.267
1II4 CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 Deposited 2001-04-20 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain F 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366
Mutation:S252W No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.70 Å R-free 0.267
1II4 CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 Deposited 2001-04-20 Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain G 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366
Mutation:S252W No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.70 Å R-free 0.267
1II4 CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 Deposited 2001-04-20 Assembly 4 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain H 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366
Mutation:S252W No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.70 Å R-free 0.267
1IIL CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 Deposited 2001-04-23 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain E 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366
Mutation:P253R No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.30 Å R-free 0.259
1IIL CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 Deposited 2001-04-23 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain F 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366
Mutation:P253R No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.30 Å R-free 0.259
1IIL CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 Deposited 2001-04-23 Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain G 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366
Mutation:P253R No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.30 Å R-free 0.259
1IIL CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 Deposited 2001-04-23 Assembly 4 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain H 147–366(220 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366
Mutation:P253R No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.30 Å R-free 0.259
1NUN Crystal Structure Analysis of the FGF10-FGFR2b Complex Deposited 2003-01-31 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 140–369(230 aa)
Non-standard monomer:Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 2 15P POLYETHYLENE GLYCOL (N=34) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;298 K;PEG 400, ammonium sulfate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.90 Å R-free 0.288
1OEC FGFr2 kinase domain Deposited 2003-03-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 456–768(313 aa) Fragment:TYROSINE KINASE DOMAIN, RESIDUES 456-768
Not recorded SO4 SULFATE ION × 8 AA2 4-ARYL-2-PHENYLAMINO PYRIMIDINE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.9;pH 5.90
Resolution 2.40 Å R-free 0.285
2PSQ Crystal Structure of Unphosphorylated Unactivated Wild Type FGF Receptor 2 (FGFR2) Kinase Domain Deposited 2007-05-07 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 413–768(356 aa) Fragment:Kinase Domain
Chain B 413–768(356 aa) Fragment:Kinase Domain
Not recorded SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 20% PEG 4000, 200mM (NH4)2SO4, 3% C2H4O, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.40 Å R-free 0.258
2PVF Crystal Structure of Tyrosine Phosphorylated Activated FGF Receptor 2 (FGFR2) Kinase Domain in Complex with ATP Analog and Substrate Peptide Deposited 2007-05-09 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–778(321 aa) Fragment:human FGF Receptor 2 Kinase Domain
Chain B 764–778(15 aa) Fragment:Peptide Stubstrate
Mutation:C491A Non-standard monomer:Yes (specific site not provided by mmCIF) MG MAGNESIUM ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 27% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.80 Å R-free 0.265
2PVY Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome. Deposited 2007-05-10 Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Kinase Domain
Chain B 458–768(311 aa) Fragment:Kinase Domain
Chain C 458–768(311 aa) Fragment:Kinase Domain
Chain D 458–768(311 aa) Fragment:Kinase Domain
Mutation:C491A, K659N Mutation:C491A, K659N Mutation:C491A, K659N Mutation:C491A, K659N SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.20 Å R-free 0.276
2PWL Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549H Mutation Responsible for Crouzon Syndrome. Deposited 2007-05-11 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Kinase Domain
Chain B 458–768(311 aa) Fragment:Kinase Domain
Mutation:C491A, N549H Mutation:C491A, N549H SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 8% C3H5(OH)3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.40 Å R-free 0.238
2PY3 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565G Mutation Responsible for Pfeiffer Syndrome Deposited 2007-05-15 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Kinase Domain
Chain B 458–768(311 aa) Fragment:Kinase Domain
Mutation:C491A, E565G Mutation:C491A, E565G SO4 SULFATE ION × 4 MG MAGNESIUM ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 2% C3H5(OH)3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.252
2PZ5 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549T Mutation Responsible for Pfeiffer Syndrome Deposited 2007-05-17 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Kinase Domain
Chain B 458–768(311 aa) Fragment:Kinase Domain
Mutation:C491A, N549T Mutation:C491A, N549T SO4 SULFATE ION × 4 MG MAGNESIUM ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.40 Å R-free 0.254
2PZP Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K526E Mutation Responsible for Crouzon Syndrome Deposited 2007-05-18 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Kinase Domain
Chain B 458–768(311 aa) Fragment:Kinase Domain
Mutation:C491A, K526E Mutation:C491A, K526E SO4 SULFATE ION × 4 MG MAGNESIUM ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.40 Å R-free 0.251
2PZR Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K641R Mutation Responsible for Pfeiffer Syndrome Deposited 2007-05-18 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Kinase Domain
Chain B 458–768(311 aa) Fragment:Kinase Domain
Mutation:C491A, K641R Mutation:C491A, K641R SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 28% PEG 4000, 300mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.00 Å R-free 0.268
2Q0B Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565A Mutation Responsible for Pfeiffer Syndrome Deposited 2007-05-21 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Kinase Domain
Chain B 458–768(311 aa) Fragment:Kinase Domain
Mutation:C491A, E565A Mutation:C491A, E565A SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 19% PEG 4000, 300mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.90 Å R-free 0.252
3B2T Structure of phosphotransferase Deposited 2007-10-19 Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 458–768(311 aa) Fragment:UNP residues 458-768
Chain B 458–768(311 aa) Fragment:UNP residues 458-768
Mutation:A628T, E767Q Mutation:A628T, E767Q PO4 PHOSPHATE ION × 8 M33 5'-O-[(S)-hydroxy{[(S)-hydroxy(methyl)phosphoryl]oxy}phosphoryl]adenosine × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;0.6M sodium dihydrogen phosphate, 0.6M potassium dihydrogen phosphate, 0.1M HEPES, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.80 Å R-free 0.233
3B2T Structure of phosphotransferase Deposited 2007-10-19 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:UNP residues 458-768
Chain B 458–768(311 aa) Fragment:UNP residues 458-768
Mutation:A628T, E767Q Mutation:A628T, E767Q PO4 PHOSPHATE ION × 4 M33 5'-O-[(S)-hydroxy{[(S)-hydroxy(methyl)phosphoryl]oxy}phosphoryl]adenosine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;0.6M sodium dihydrogen phosphate, 0.6M potassium dihydrogen phosphate, 0.1M HEPES, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.80 Å R-free 0.233
3CAF Crystal Structure of hFGFR2 D2 Domain Deposited 2008-02-19 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 150–249(100 aa) Fragment:Ig-like C2-type 2
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;20%(w/v) PEG3350, 0.1M (NH3)2SO4, 100mM HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.96 Å R-free 0.275
3CAF Crystal Structure of hFGFR2 D2 Domain Deposited 2008-02-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 150–249(100 aa) Fragment:Ig-like C2-type 2
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;20%(w/v) PEG3350, 0.1M (NH3)2SO4, 100mM HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.96 Å R-free 0.275
3CLY Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domains Trapped in Trans-Phosphorylation Reaction Deposited 2008-03-20 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–778(321 aa) Fragment:Protein Kinase Domain
Mutation:C491A Non-standard monomer:Yes (specific site not provided by mmCIF) MG MAGNESIUM ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100 mM HEPES pH7.5, 26% PEG 4000, 200 mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.247
3CLY Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domains Trapped in Trans-Phosphorylation Reaction Deposited 2008-03-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–778(321 aa) Fragment:Protein Kinase Domain
Mutation:C491A Non-standard monomer:Yes (specific site not provided by mmCIF) MG MAGNESIUM ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100 mM HEPES pH7.5, 26% PEG 4000, 200 mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.247
3CU1 Crystal Structure of 2:2:2 FGFR2D2:FGF1:SOS complex Deposited 2008-04-15 Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 150–249(100 aa) Fragment:Ig-like C2-type 2 domain, UNP residues 150-249
Chain C 150–249(100 aa) Fragment:Ig-like C2-type 2 domain, UNP residues 150-249
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;12% PEG3350, 4% Tacsimate, pH 7.0, vapor diffusion, hanging drop, temperature 298.0K
Resolution 2.60 Å R-free 0.277
3DAR Crystal structure of D2 domain from human FGFR2 Deposited 2008-05-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 146–249(104 aa) Fragment:D2 domain, Ig-like C2-type 2, UNP residues 146-249
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;291 K;0.2 M sodium acetate, 0.1 M Tris-HCl, 30% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K, pH 8.5
Resolution 2.20 Å R-free 0.255
3DAR Crystal structure of D2 domain from human FGFR2 Deposited 2008-05-30 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 146–249(104 aa) Fragment:D2 domain, Ig-like C2-type 2, UNP residues 146-249
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;291 K;0.2 M sodium acetate, 0.1 M Tris-HCl, 30% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K, pH 8.5
Resolution 2.20 Å R-free 0.255
3EUU Crystal structure of the FGFR2 D2 domain Deposited 2008-10-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 150–249(100 aa) Fragment:UNP residues 150-249
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.8M ammonium citrate dibasic, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.34 Å R-free 0.228
3EUU Crystal structure of the FGFR2 D2 domain Deposited 2008-10-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 150–249(100 aa) Fragment:UNP residues 150-249
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.8M ammonium citrate dibasic, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.34 Å R-free 0.228
3EUU Crystal structure of the FGFR2 D2 domain Deposited 2008-10-10 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 150–249(100 aa) Fragment:UNP residues 150-249
Chain B 150–249(100 aa) Fragment:UNP residues 150-249
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.8M ammonium citrate dibasic, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.34 Å R-free 0.228
3OJ2 Crystal structure of FGF1 complexed with the ectodomain of FGFR2b harboring the A172F Pfeiffer syndrome mutation Deposited 2010-08-20 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 140–313(174 aa)
Mutation:A172F SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1M Hepes, 20% PEG4000, 0.2M ammonium sulfate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.294
3OJ2 Crystal structure of FGF1 complexed with the ectodomain of FGFR2b harboring the A172F Pfeiffer syndrome mutation Deposited 2010-08-20 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain D 140–313(174 aa)
Mutation:A172F SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1M Hepes, 20% PEG4000, 0.2M ammonium sulfate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.294
3OJM Crystal Structure of FGF1 complexed with the ectodomain of FGFR2b harboring P253R Apert mutation Deposited 2010-08-23 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 140–313(174 aa) Fragment:FGFR2b
Mutation:P253R SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1M Hepes, 22% monomethyl ether PEG5000, 0.2M ammonium sulfate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.10 Å R-free 0.263
3RI1 Crystal structure of the catalytic domain of FGFR2 kinase in complex with ARQ 069 Deposited 2011-04-12 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa) Fragment:UNP residues 458-768
Not recorded 3RH (6S)-6-phenyl-5,6-dihydrobenzo[h]quinazolin-2-amine × 1 SO4 SULFATE ION × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;15% polyethylene glycol 4000 and 0.3M lithium sulfate and 100 mM HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.247
3RI1 Crystal structure of the catalytic domain of FGFR2 kinase in complex with ARQ 069 Deposited 2011-04-12 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa) Fragment:UNP residues 458-768
Not recorded 3RH (6S)-6-phenyl-5,6-dihydrobenzo[h]quinazolin-2-amine × 1 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;15% polyethylene glycol 4000 and 0.3M lithium sulfate and 100 mM HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.247
4J23 Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex Deposited 2013-02-04 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 147–366(220 aa) Fragment:unp residues 147-366
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.88 Å R-free 0.384
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. Deposited 2013-02-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659N ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. Deposited 2013-02-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659N ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. Deposited 2013-02-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659N ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. Deposited 2013-02-15 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659N ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. Deposited 2013-02-15 Assembly 5 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659N Mutation:C491A, K659N ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. Deposited 2013-02-15 Assembly 6 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Chain D 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659N Mutation:C491A, K659N ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.38 Å R-free 0.255
4J96 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer. Deposited 2013-02-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659M SO4 SULFATE ION × 1 FLC CITRATE ANION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.219
4J96 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer. Deposited 2013-02-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659M SO4 SULFATE ION × 2 FLC CITRATE ANION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.219
4J96 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer. Deposited 2013-02-15 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659M Mutation:C491A, K659M SO4 SULFATE ION × 3 FLC CITRATE ANION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.219
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. Deposited 2013-02-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659E ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. Deposited 2013-02-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659E ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. Deposited 2013-02-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659E ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. Deposited 2013-02-15 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659E ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. Deposited 2013-02-15 Assembly 5 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Chain C 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659E Mutation:C491A, K659E ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. Deposited 2013-02-15 Assembly 6 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Chain D 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659E Mutation:C491A, K659E ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.257
4J98 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659Q Mutation. Deposited 2013-02-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659Q SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.31 Å R-free 0.234
4J98 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659Q Mutation. Deposited 2013-02-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659Q SO4 SULFATE ION × 3 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.31 Å R-free 0.234
4J98 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659Q Mutation. Deposited 2013-02-15 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659Q Mutation:C491A, K659Q SO4 SULFATE ION × 5 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.31 Å R-free 0.234
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. Deposited 2013-02-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659T SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. Deposited 2013-02-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659T SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. Deposited 2013-02-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659T SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. Deposited 2013-02-15 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659T SO4 SULFATE ION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. Deposited 2013-02-15 Assembly 5 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Chain B 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659T Mutation:C491A, K659T SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. Deposited 2013-02-15 Assembly 6 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Chain D 458–768(311 aa) Fragment:Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)
Mutation:C491A, K659T Mutation:C491A, K659T SO4 SULFATE ION × 3 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 MG MAGNESIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.240
4WV1 Crystal structure of the FGFR2 D2 domain in complex with Fab 2B.1.3 Deposited 2014-11-04 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain F 153–251(99 aa) Fragment:UNP residues 153-251
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;292 K;PEG 3350, potassium nitrate
Resolution 2.36 Å R-free 0.244
4WV1 Crystal structure of the FGFR2 D2 domain in complex with Fab 2B.1.3 Deposited 2014-11-04 Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain C 153–251(99 aa) Fragment:UNP residues 153-251
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;292 K;PEG 3350, potassium nitrate
Resolution 2.36 Å R-free 0.244
5EG3 Crystal Structure of the Activated FGF Receptor 2 (FGFR2) Kinase Domain in complex with the cSH2 domain of Phospholipase C gamma (PLCgamma) Deposited 2015-10-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–778(321 aa) Fragment:UNP residues 458-778
Mutation:Y466F, C491A, E565A, Y586L, Y588P, Y656F, Y657F, K659E Non-standard monomer:Yes (specific site not provided by mmCIF) ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;25 mM HEPES (pH 7.5), PEG20000 (12% 18%) and 2% (w/v) Benzamidine hydrochloride
Resolution 2.61 Å R-free 0.237
5UGL Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation Deposited 2017-01-09 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 341–651(311 aa) Fragment:UNP residues 341-651
Mutation:D650V SO4 SULFATE ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;25 mM HEPES pH7.5, 15%-25% w/v PEG4000, 0.2-0.3 M NH4SO3
Resolution 1.86 Å R-free 0.258
5UGL Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation Deposited 2017-01-09 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 341–651(311 aa) Fragment:UNP residues 341-651
Mutation:D650V SO4 SULFATE ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;25 mM HEPES pH7.5, 15%-25% w/v PEG4000, 0.2-0.3 M NH4SO3
Resolution 1.86 Å R-free 0.258
5UGX Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 Harboring a E565A/D650V double Gain-of-Function Mutation Deposited 2017-01-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 341–651(311 aa) Fragment:UNP residues 341-651
Mutation:E565A, D650V SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;25 mM HEPES (pH 7.5), 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium sulfate
Resolution 2.35 Å R-free 0.275
5UGX Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 Harboring a E565A/D650V double Gain-of-Function Mutation Deposited 2017-01-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 341–651(311 aa) Fragment:UNP residues 341-651
Mutation:E565A, D650V SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;25 mM HEPES (pH 7.5), 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium sulfate
Resolution 2.35 Å R-free 0.275
5UHN Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring a N549H/E565A Double Gain-of-Function Mutation Deposited 2017-01-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 342–652(311 aa) Fragment:UNP residues 342-652
Mutation:N549H, E565A SO4 SULFATE ION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;25 mM HEPES (pH 7.5), 15-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate
Resolution 2.91 Å R-free 0.311
5UHN Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring a N549H/E565A Double Gain-of-Function Mutation Deposited 2017-01-11 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 342–652(311 aa) Fragment:UNP residues 342-652
Mutation:N549H, E565A SO4 SULFATE ION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;25 mM HEPES (pH 7.5), 15-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate
Resolution 2.91 Å R-free 0.311
5UI0 Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring an E565A/K659M Double Gain-of-Function Mutation Deposited 2017-01-12 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 341–651(311 aa) Fragment:UNP residues 341-651
Mutation:E565A, K659M FLC CITRATE ANION × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;25 mM HEPES pH 7.5, 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate
Resolution 2.05 Å R-free 0.207
5UI0 Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring an E565A/K659M Double Gain-of-Function Mutation Deposited 2017-01-12 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 341–651(311 aa) Fragment:UNP residues 341-651
Mutation:E565A, K659M FLC CITRATE ANION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;25 mM HEPES pH 7.5, 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate
Resolution 2.05 Å R-free 0.207
6AGX The cocrystal structure of FGFR2 bound with compound 14 harboring 5H-pyrrolo[2,3-b]pyrazine scaffold Deposited 2018-08-15 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 467–764(298 aa) Fragment:UNP residues 467-764
Chain B 467–764(298 aa) Fragment:UNP residues 467-764
Mutation:A628T Non-standard monomer:Yes (specific site not provided by mmCIF) Mutation:A628T Non-standard monomer:Yes (specific site not provided by mmCIF) 9WX ethyl [4-({3-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazin-5-yl}sulfonyl)-1H-imidazol-1-yl]acetate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION;pH 6.5;298 K;0.2M Ammonium sulfate, 0.1M MES pH 6.5, 30%(w/v) PEG 5000 MME
Resolution 2.95 Å R-free 0.298
6AGX The cocrystal structure of FGFR2 bound with compound 14 harboring 5H-pyrrolo[2,3-b]pyrazine scaffold Deposited 2018-08-15 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 467–764(298 aa) Fragment:UNP residues 467-764
Chain D 467–764(298 aa) Fragment:UNP residues 467-764
Mutation:A628T Non-standard monomer:Yes (specific site not provided by mmCIF) Mutation:A628T Non-standard monomer:Yes (specific site not provided by mmCIF) 9WX ethyl [4-({3-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazin-5-yl}sulfonyl)-1H-imidazol-1-yl]acetate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION;pH 6.5;298 K;0.2M Ammonium sulfate, 0.1M MES pH 6.5, 30%(w/v) PEG 5000 MME
Resolution 2.95 Å R-free 0.298
6LVK Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative Deposited 2020-02-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 459–768(310 aa)
Non-standard monomer:Yes (specific site not provided by mmCIF) EVC N-ethyl-2-[[4-[[4-(4-methylpiperazin-1-yl)-3-(2-morpholin-4-ylethoxy)phenyl]amino]-1,3,5-triazin-2-yl]amino]benzenesulfonamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;296 K;Tris, Ammonium sulfate, PEG 8000
Resolution 2.29 Å R-free 0.247
6LVK Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative Deposited 2020-02-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 459–768(310 aa)
Non-standard monomer:Yes (specific site not provided by mmCIF) EVC N-ethyl-2-[[4-[[4-(4-methylpiperazin-1-yl)-3-(2-morpholin-4-ylethoxy)phenyl]amino]-1,3,5-triazin-2-yl]amino]benzenesulfonamide × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;296 K;Tris, Ammonium sulfate, PEG 8000
Resolution 2.29 Å R-free 0.247
6LVL Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative Deposited 2020-02-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 459–768(310 aa)
Not recorded SO4 SULFATE ION × 1 EVL N-ethyl-2-[[4-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-1,3,5-triazin-2-yl]amino]benzenesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;296 K;Tris, Ammonium sulfate, PEG 8000
Resolution 2.98 Å R-free 0.251
6LVL Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative Deposited 2020-02-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 459–768(310 aa)
Not recorded SO4 SULFATE ION × 3 EVL N-ethyl-2-[[4-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-1,3,5-triazin-2-yl]amino]benzenesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;296 K;Tris, Ammonium sulfate, PEG 8000
Resolution 2.98 Å R-free 0.251
6V6Q Crystal Structure of Monophosphorylated FGF Receptor 2 isoform IIIb with PTR657 Deposited 2019-12-05 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 413–821(409 aa)
Chain B 413–821(409 aa)
Mutation:Y467F,Y562F,Y576F,Y587F,Y589F,Y609F,Y617F,Y658F,Y734F Non-standard monomer:Yes (specific site not provided by mmCIF) Mutation:Y467F,Y562F,Y576F,Y587F,Y589F,Y609F,Y617F,Y658F,Y734F Non-standard monomer:Yes (specific site not provided by mmCIF) ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.6;293 K;160mM TMAO, 20% PEG 2000, 100mM Tris pH 8.6
Resolution 2.46 Å R-free 0.239
6V6Q Crystal Structure of Monophosphorylated FGF Receptor 2 isoform IIIb with PTR657 Deposited 2019-12-05 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 413–821(409 aa)
Chain D 413–821(409 aa)
Mutation:Y467F,Y562F,Y576F,Y587F,Y589F,Y609F,Y617F,Y658F,Y734F Non-standard monomer:Yes (specific site not provided by mmCIF) Mutation:Y467F,Y562F,Y576F,Y587F,Y589F,Y609F,Y617F,Y658F,Y734F Non-standard monomer:Yes (specific site not provided by mmCIF) ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.6;293 K;160mM TMAO, 20% PEG 2000, 100mM Tris pH 8.6
Resolution 2.46 Å R-free 0.239
7KIA Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 19 Deposited 2020-10-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 461–768(308 aa) Fragment:Kinase domain, residues 461-768
Mutation:V564F WFD 1-[4-(4-{4-(4-methylpiperazin-1-yl)-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}phenyl)piperidin-1-yl]prop-2-en-1-one × 1 FLC CITRATE ANION × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 4;298 K;12% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0
Resolution 2.22 Å R-free 0.223
7KIA Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 19 Deposited 2020-10-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 461–768(308 aa) Fragment:Kinase domain, residues 461-768
Mutation:V564F WFD 1-[4-(4-{4-(4-methylpiperazin-1-yl)-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}phenyl)piperidin-1-yl]prop-2-en-1-one × 1 FLC CITRATE ANION × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 4;298 K;12% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0
Resolution 2.22 Å R-free 0.223
7KIE Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 3 Deposited 2020-10-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 461–768(308 aa) Fragment:Kinase domain, residues 461-768
Mutation:V564F WF7 N-{4-[(E)-2-{4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}ethenyl]phenyl}prop-2-enamide × 1 FLC CITRATE ANION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 4;298 K;15% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0
Resolution 2.47 Å R-free 0.229
7KIE Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 3 Deposited 2020-10-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 461–768(308 aa) Fragment:Kinase domain, residues 461-768
Mutation:V564F WF7 N-{4-[(E)-2-{4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}ethenyl]phenyl}prop-2-enamide × 1 FLC CITRATE ANION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 4;298 K;15% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0
Resolution 2.47 Å R-free 0.229
7OZY FGFR2 kinase domain (residues 461-763) in complex with 38. Deposited 2021-06-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain AAA 465–763(299 aa)
Not recorded 47I 4-[3-(4-piperazin-4-ium-1-ylphenyl)-1H-indazol-6-yl]phenol × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.6;291 K;25% w/v PEG 3350, 0.1 M ammonium sulfate, 0.1 M HEPES
Resolution 2.28 Å R-free 0.296
7OZY FGFR2 kinase domain (residues 461-763) in complex with 38. Deposited 2021-06-29 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain BBB 465–763(299 aa)
Not recorded 47I 4-[3-(4-piperazin-4-ium-1-ylphenyl)-1H-indazol-6-yl]phenol × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.6;291 K;25% w/v PEG 3350, 0.1 M ammonium sulfate, 0.1 M HEPES
Resolution 2.28 Å R-free 0.296
8E1X FGFR2 kinase domain in complex with a Pyrazolo[1,5-a]pyrimidine analog (Compound 29) Deposited 2022-08-11 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 459–768(310 aa)
Chain B 459–768(310 aa)
Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) U9P (5M)-N-methyl-5-{(6M,8S)-5-{[(3S)-oxolan-3-yl]amino}-6-[1-(propan-2-yl)-1H-pyrazol-3-yl]pyrazolo[1,5-a]pyrimidin-3-yl}pyridine-3-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5.2;293 K;0.1 M Sodium citrate pH 5.2; 28% w/w PEG 4,000; 0.2 M Ammonium acetate
Resolution 2.68 Å R-free 0.272
8H75 FGFR2 in complex with YJ001 Deposited 2022-10-19 Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 347–656(310 aa)
Chain B 347–656(310 aa)
Chain C 347–656(310 aa)
Chain D 347–656(310 aa)
Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) KX0 Tinengotinib × 4 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6;293 K;0.2M (NH4)2SO4, 0.1M Bis-Tris pH6.0, 25% PEG3350.
Resolution 3.75 Å R-free 0.238
8STG Discovery and clinical validation of RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations Deposited 2023-05-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–769(312 aa) Fragment:kinase domain (UNP residues 458-769)
Not recorded WCJ N-{4-[(5P)-4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-2-methylpropanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;291.15 K;0.1 M Tris, pH 8, 18-20% w/v PEG8000
Resolution 3.79 Å R-free 0.311
8STG Discovery and clinical validation of RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations Deposited 2023-05-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–769(312 aa) Fragment:kinase domain (UNP residues 458-769)
Not recorded WCJ N-{4-[(5P)-4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-2-methylpropanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;291.15 K;0.1 M Tris, pH 8, 18-20% w/v PEG8000
Resolution 3.79 Å R-free 0.311
8SWE FGFR2 Kinase Domain Bound to Reversible Inhibitor Cmpd 3 Deposited 2023-05-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Not recorded GOL GLYCEROL × 1 GSH Glutathione × 1 WXQ N-{4-[4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;291.15 K;27 % PEG 4000, 0.1 M Hepes pH7.5, 0.252 M Ammonium Sulfate, 0.05 M GSH GSSG
Resolution 2.24 Å R-free 0.250
8SWE FGFR2 Kinase Domain Bound to Reversible Inhibitor Cmpd 3 Deposited 2023-05-18 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Not recorded GOL GLYCEROL × 3 WXQ N-{4-[4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;291.15 K;27 % PEG 4000, 0.1 M Hepes pH7.5, 0.252 M Ammonium Sulfate, 0.05 M GSH GSSG
Resolution 2.24 Å R-free 0.250
8U1F FGFR2 Kinase Domain Bound to Irreversible Inhibitor Cmpd 10 Deposited 2023-08-31 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–768(311 aa)
Chain B 458–768(311 aa)
Not recorded GOL GLYCEROL × 1 UIM N-[4-(4-amino-7-methyl-5-{4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]-2-methylpropanamide × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;0.1 M Tris pH 8, 18% PEG K
Resolution 3.33 Å R-free 0.295
8W2X TAS-120 covalent structure with FGFR2 Deposited 2024-02-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Mutation:D650V A1AFR 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]propan-1-one × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.6;293 K;0.2 M Potassium sodium tartrate tetrahydrate 2.0 M Ammonium sulfate 0.1 M Sodium citrate 5.6
Resolution 2.98 Å R-free 0.237
8W2X TAS-120 covalent structure with FGFR2 Deposited 2024-02-21 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Mutation:D650V A1AFR 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]propan-1-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.6;293 K;0.2 M Potassium sodium tartrate tetrahydrate 2.0 M Ammonium sulfate 0.1 M Sodium citrate 5.6
Resolution 2.98 Å R-free 0.237
8W38 TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Mutation:N549D, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;291 K;25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH 7.5
Resolution 2.60 Å R-free 0.359
8W38 TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Mutation:N549D, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;291 K;25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH 7.5
Resolution 2.60 Å R-free 0.359
8W38 TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–768(311 aa)
Mutation:N549D, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;291 K;25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH 7.5
Resolution 2.60 Å R-free 0.359
8W38 TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–768(311 aa)
Mutation:N549D, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;291 K;25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH 7.5
Resolution 2.60 Å R-free 0.359
8W3B TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Mutation:N549H, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.2;291 K;0.2 M Lithium sulfate, 0.1 M HEPES 7.2, 25 % v/v PEG Smear Broad
Resolution 2.23 Å R-free 0.312
8W3B TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Mutation:N549H, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.2;291 K;0.2 M Lithium sulfate, 0.1 M HEPES 7.2, 25 % v/v PEG Smear Broad
Resolution 2.23 Å R-free 0.312
8W3B TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–768(311 aa)
Mutation:N549H, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.2;291 K;0.2 M Lithium sulfate, 0.1 M HEPES 7.2, 25 % v/v PEG Smear Broad
Resolution 2.23 Å R-free 0.312
8W3B TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–768(311 aa)
Mutation:N549H, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.2;291 K;0.2 M Lithium sulfate, 0.1 M HEPES 7.2, 25 % v/v PEG Smear Broad
Resolution 2.23 Å R-free 0.312
8W3D TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Mutation:N549K, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;291 K;0.2 M Lithium sulfate 0.1 M Bis-Tris 6.5 25 % w/v PEG 3350
Resolution 2.04 Å R-free 0.250
8W3D TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Mutation:N549K, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;291 K;0.2 M Lithium sulfate 0.1 M Bis-Tris 6.5 25 % w/v PEG 3350
Resolution 2.04 Å R-free 0.250
8W3D TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–768(311 aa)
Mutation:N549K, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;291 K;0.2 M Lithium sulfate 0.1 M Bis-Tris 6.5 25 % w/v PEG 3350
Resolution 2.04 Å R-free 0.250
8W3D TAS-120 covalent structure with FGFR2 molecular brake mutant Deposited 2024-02-22 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–768(311 aa)
Mutation:N549K, D650V TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;291 K;0.2 M Lithium sulfate 0.1 M Bis-Tris 6.5 25 % w/v PEG 3350
Resolution 2.04 Å R-free 0.250
9U3N Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with compound LC-F2-01 Deposited 2025-03-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–768(311 aa)
Mutation:V564F A1ENT ~{N}-[4-[4-azanyl-7-methyl-5-[2-(3-methylimidazo[4,5-b]pyridin-6-yl)ethynyl]pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;0.2M Sodium formate, 20% PEG3,3500+16% Glutaric acid, 0.16% Mellitic acid, 0.16% Oxalic acid, 0.16% Pimelic acid, 0.16% Sebacic acid,0.16% trans-Cinnamic acid, 0.02 M HEPES Na pH6.8
Resolution 3.25 Å R-free 0.342
9U3N Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with compound LC-F2-01 Deposited 2025-03-18 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–768(311 aa)
Mutation:V564F A1ENT ~{N}-[4-[4-azanyl-7-methyl-5-[2-(3-methylimidazo[4,5-b]pyridin-6-yl)ethynyl]pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;0.2M Sodium formate, 20% PEG3,3500+16% Glutaric acid, 0.16% Mellitic acid, 0.16% Oxalic acid, 0.16% Pimelic acid, 0.16% Sebacic acid,0.16% trans-Cinnamic acid, 0.02 M HEPES Na pH6.8
Resolution 3.25 Å R-free 0.342
9U7E FGFR2 kinase domain with a macrocyclic compound 8g Deposited 2025-03-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 465–768(304 aa)
Chain B 465–768(304 aa)
Not recorded A1EOH (E)-4-methyl-17-(1-methyl-1H-pyrazol-4-yl)-7,10-dioxa-4-aza-1(3,6)-imidazo[1,2-b]pyridazina-2(3,5)-pyridinacyclodecaphan-3-one × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293.15 K;16% PEG 3350, 100 mM (NH4)2SO4, 100 mM HEPES, pH 7.5
Resolution 2.20 Å R-free 0.312
9U7S FGFR2 kinase domain with a macrocyclic compound 8r Deposited 2025-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 465–768(304 aa)
Chain B 465–768(304 aa)
Not recorded A1EOJ (E)-4-methyl-17-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-7,10-dioxa-4-aza-1(3,6)-imidazo[1,2-b]pyridazina-2(1,3)-benzenacyclodecaphan-3-one × 2 SO4 SULFATE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293.15 K;18% PEG 3350, 100 mM (NH4)2SO4, 100 mM HEPES, pH 7.5
Resolution 1.99 Å R-free 0.225
9VLM The X-RAY co-crystal structure of human FGFR2 and covalent inhibitor 10a Deposited 2025-06-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 465–765(301 aa)
Not recorded A1ESP ~{N}-[3-[2-[[3-[2-(dimethylamino)ethylsulfamoylmethyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-indol-6-yl]propanamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;22% (w/v) PEG 8000, and 0.1 M Tris-HCl, pH 8.0
Resolution 2.26 Å R-free 0.254
9VLM The X-RAY co-crystal structure of human FGFR2 and covalent inhibitor 10a Deposited 2025-06-25 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 465–765(301 aa)
Not recorded A1ESP ~{N}-[3-[2-[[3-[2-(dimethylamino)ethylsulfamoylmethyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-indol-6-yl]propanamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;22% (w/v) PEG 8000, and 0.1 M Tris-HCl, pH 8.0
Resolution 2.26 Å R-free 0.254